Compare The Coca-Cola Co K (KO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Pfizer Inc — how do they compare? The Coca-Cola Co K trades at $86.57 (market cap $373.76B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: The Coca-Cola Co K is far larger — about 2.4× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| KO | PFE | |
|---|---|---|
Market Cap | $373.76B | $154.18B |
Volume | 14,630,257 | 29,869,932 |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $28.56 |
52-Week Low | $65.67 | $23.60 |
Enterprise Value | $400.93B | $205.67B |
Dividend Yield | 2.44% | 6.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.48, down 0.65% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 estimate, and maintains robust profitability with a 28.56% net margin. Recent news highlights institutional buying and stable demand trends, while dividends continue with a $0.53 payout.
The outlook is positive with a consensus price target of $95.83 implying 11% upside, driven by earnings momentum and dividend reliability. Risks include regional demand volatility and high debt levels, but analyst sentiment is bullish with 60% buy ratings. The stock presents a steady growth opportunity with defensive income characteristics.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
